Adamax Pharmacokinetics
Adamax half-life, absorption, routes of administration, and clearance.
Half-Life and Stability
No formal pharmacokinetic study has been published for Adamax in humans or animals. Estimated half-life is approximately 2–4 hours based on Semax analog data, though the N-terminal acetyl group and adamantyl modification are specifically designed to extend enzymatic stability relative to native Semax. The acetyl group protects against aminopeptidase degradation; the adamantane group is hypothesized to reduce renal clearance through its lipophilic cage structure. These are mechanistic hypotheses, not confirmed human PK data.
Administration Routes and Absorption
Adamax is administered by intranasal spray or subcutaneous injection in research settings. The intranasal route is preferred for Semax-class analogs because it bypasses the blood-brain barrier via the olfactory epithelium and trigeminal nerve pathways, delivering compound directly to CNS tissue. However, the adamantane modification's enhanced blood-brain barrier penetration profile may make systemic subcutaneous dosing equally viable in preclinical models. Absorption kinetics, bioavailability, and Tmax values have not been formally published for Adamax as a standalone compound.
Physicochemical and PK profile
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.